DOCSLIB.ORG

The Case of Multiple Sclerosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Case of Multiple Sclerosis Genes and Immunity (2004) 5, 615–620 & 2004 Nature Publishing Group All rights reserved 1466-4879/04 $30.00 www.nature.com/gene FULL PAPER Intergenomic consensus in multifactorial inheritance loci: the case of multiple sclerosis P Serrano-Ferna´ndez1, SM Ibrahim1, UK Zettl2, H-J Thiesen1,RGo¨dde3, JT Epplen3 and S Mo¨ller1 1Institute of Immunology, University of Rostock, Schillingallee 70, Rostock, Germany; 2Institute of Neurology, University of Rostock, Gehlsheimer Strae 20, Rostock, Germany; 3Department of Human Genetics, University of Bochum, Bochum, Germany Genetic linkage and association studies define chromosomal regions, quantitative trait loci (QTLs), which influence the phenotype of polygenic diseases. Here, we describe a global approach to determine intergenomic consensus of those regions in order to fine map QTLs and select particularly promising candidate genes for disease susceptibility or other polygenic traits. Exemplarily, human multiple sclerosis (MS) susceptibility regions were compared for sequence similarity with mouse and rat QTLs in its animal model experimental allergic encephalomyelitis (EAE). The number of intergenomic MS/EAE consensus genes (295) is significantly higher than expected if the animal model was unrelated to the human disease. Hence, this approach contributes to the empirical evaluation of animal models for their applicability to the study of human diseases. Genes and Immunity (2004) 5, 615–620. doi:10.1038/sj.gene.6364134 Keywords: multiple sclerosis (MS); experimental allergic encephalomyelitis (EAE); quantitative trait locus (QTL); intergenomics; comparative genomics Introduction of loci and genes that presumably affect the phenotype of polygenic traits shared by multiple species. Genetic linkage analyses on individuals suffering from a QTL mapping efforts have been performed indepen- polygenic disease and their relatives help to identify dently for several species for the same traits. If the chromosomal regions responsible for susceptibility and animal models are driven by the same genetic for particular traits of the disease (quantitative trait loci, mechanisms as those for the human diseases, we QTLs). Such analyses have proven successful to identify should expect to find common conserved sequences genes and pathways determining the pathogenesis.1 shared by QTLs and susceptibility regions of all three The process of reducing a previously determined organisms. Genes in those shared sequences are best QTL is referred to as fine mapping. Unfortunately, candidates to be relevant for the onset and/or further classical approaches for fine-mapping are time and cost development of the disease. Barton et al9 evidenced this intensive and experimentally complex.2 In order to save as they identified a new susceptibility region for resources, other techniques are used to direct the rheumatoid arthritis supported by syntenic correspon- analysis of larger QTLs, for example, global analysis dence to QTLs of an animal model. Xu et al10 identified of single-nucleotide polymorphisms (SNPs),3 large scale by the same principle new susceptibility regions sequencing and gene expression profiling.1 The latter associated with MS and syntenic to QTLs of different point to genes that are differentially expressed in experimental autoimmune diseases in the rat. Here, we diseased animals, thus setting preferences among expand that prospective approach to a systematic candidate genes within a QTL. This has been performed retrospective comparison of the human disease with recently4 for the mouse experimental autoimmune combined information from multiple animal models encephalomyelitis (EAE). EAE is recognized as the best and different species at a genome-wide scale to fine animal model for multiple sclerosis (MS), one of the map already known susceptibility regions, and provide most common human neurological diseases. Both are an estimation of the validity of those models for the subject of the present study. human disease. Intergenomic approaches have focused mainly on phylogeny,5 genetic transfer,6 gene functionality7 and the prediction of genes or regulatory regions.8 Here, we introduce an in silico approach for a genome-wide search Results Fine mapping QTLs involved in rat EAE extend over a total size of 200 Mbp. They were scanned for synteny with the mouse Correspondence: Dr P Serrano-Ferna´ndez, Institute of Immunology, University of Rostock, Schillingallee 70, 18055 Rostock, Germany. genome on the basis of a minimum of 90% sequence E-mail: [email protected] similarity. The EnsEMBL ‘compara’ database yielded Received 17 March 2004; revised and accepted 03 August 2004 46 000 syntenic DNA segments with sizes ranging Intergenomic consensus in multiple sclerosis P Serrano-Ferna´ndez et al 616 between 100 bp and 150 kbp. Those segments were More strictly, if we consider only those regions affected merged (see Materials and methods) into 29 000 se- by consensuses, the reduction is 98.8% for human quences. Of these sequences, 11 300 were located within susceptibility loci (from 100 to 1.2 Mbp). EAE QTLs of the mouse and extended over 5.3 Mbp. The subsequent scan of the human genome for syntenic regions with at least 60% similarity with the Consensus genes aforementioned 11 300 chromosomal regions in mouse A total of 242 genes are mapped completely or partially EAE QTLs yielded 10 900 smaller DNA fragments, which inside the consensus regions. Additionally, we searched were merged into 4200 larger DNA sequences. A total of for further common genes by means of pair-wise gene 1600 comprised genes that had been previously de- homology (see methods). A total of 251 genes were found scribed as candidates for the human MS or were located in this way; 198 of them are shared with the former set. A in regions predisposing to MS. Those sequences con- total of 44 genes are found exclusively by means of stitute 14 major consensus regions (Table 1) distributed synteny search and 53 genes only by homology search. over five chromosomes (1, 5, 6, 17 and 18) and spanning The combination of both sets of genes features a total of over 1.2 Mbp (Figure 1). 295 particularly interesting candidate genes valid for all In the first step, the consensuses between rodents three species (Supplementary Table 1). Those genes with reduce the size of QTLs associated with EAE by 97.4% evidence for association with MS have been highlighted for the rat (from 200 to 5.3 Mbp) and by 99.2% for the in Table 1. mouse (from 630 to 5.3 Mbp). These rodent consensuses The aforementioned reduction of susceptibility regions are reduced again in the second step to those shared affected by consensuses can also be expressed in terms of additionally by human MS susceptibility regions. Only genes. In the human, the 14 consensuses reduce the 22.6% of the previous rodent consensus (from 5.3 to original number of candidate genes by 76.5% (from 1257 1.2 Mbp) passes this filter. The human MS susceptibility to 295 genes) with local values ranging from 16.4% (first regions considered in this study are thus reduced by affected susceptibility region in chromosome 17) to 89% 99.8% (from 790 to 1.2 Mbp) at the end of the process. (last two affected susceptibility loci in chromosome 17). Table 1 Consensus regions for EAE/MS Bands Start-end (Mbp) References genetic association (human) Known susceptibility genes Chromosome 1 q21.3 150–150 Genes Immun 2002; 3: 279–285 q42.13 224.9–225 J Neuroimmunol 2003; 143: 124–128 Chromosome 5 q31.1 133.5–134.1 J Neuroimmunol 2003; 143: 65–69 J Neuroimmunol 2003; 143: 116–119 q33.2–34 152.9–161 Genes Immun 2001; 2: 205–210 IL12B41 Chromosome 6 p21.33–32 29.8–33.2 J Neuroimmunol 2003; 143: 60–64 TAP1, TAP212 J Neuroimmunol 2003; 143: 93–96 HLA-DMB, DRA18 J Neuroimmunol 2003; 143: 124–128 HLA-DQA, DQB19 p21.1–12.3 45.9–47.2 J Neuroimmunol 2003; 143: 60–64 J Neuroimmunol 2003; 143: 120–123 Chromosome 17 p13.2–13.1 6.2–7.5 J Neuroimmunol 2003; 143: 79–83 p13.1–12 9.7–12.2 J Neuroimmunol 2003; 143: 65–69 J Neuroimmunol 2003; 143: 124–128 q11.2 27.1–29.8 J Neuroimmunol 2003; 143: 88–92 q21.2 41 q21.31–32 44.1–46 Genes Immun 2003; 4: 559–563 q23.2 57.7 q23.3–24.2 60.9–67.6 J Neuroimmunol 2003; 143: 65–69 J Neuroimmunol 2003; 143: 124–128 PRKCA25 Genes Immun 2003; 4: 559–563 Hum Mol Genet 2002; 11: 2257–2267 q24.3–25.1 70.6–73.5 J Neuroimmunol 2003; 143: 88–92 J Neuroimmunol 2003; 143: 53–55 Chromosome 18 q21.2 49.9–50.7 J Neuroimmunol 2003; 143: 84–87 The localization of the consensuses is indicated in the first column as cytogenetic band and in the second column physically in Mbp. The following columns indicate references for the corresponding association analysis studies in human and previously described susceptibility genes included in that region (reference to the literature list in brackets), respectively. Note: for the MHC locus in chromosome 6, only a selection of references with nonfully overlapping susceptibility regions has been included in the table. Genes and Immunity Intergenomic consensus in multiple sclerosis P Serrano-Ferna´ndez et al 617 a Rattus norvegicus chr. 20 Mus musculuschr. 17 Homo sapiens chr.6 EAE1 20 Mbp 20 Mbp 40 Mbp EAE1, 5 20 Mbp 40 Mbp 80 Mbp To consensus inrat chromosome 9 100 Mbp 60 Mbp 120 Mbp 40 Mbp 140 Mbp 80 Mbp 160 Mbp b Rattus norvegicus chr. 10 Mus musculus chr. 11 Homo sapiens chr. 17 EAE6a 10 Mbp 20 Mbp EAE3 20 Mbp 20 Mbp To consensus inhuman chromosome 5 EAE6b 40 Mbp 40 Mbp 30 Mbp 40 Mbp EAE23 60 Mbp 60 Mbp 50 Mbp EAE7, 22 80 Mbp 80 Mbp 60 Mbp EAE12 100 Mbp 70 Mbp 100 Mbp 120 Mbp 80 Mbp Figure 1 Syntenic regions (blue bars) between rat and mouse chromosomes, and between mouse and human chromosomes (green bars).
Load more

Recommended publications
  • A Minimal Set of Internal Control Genes for Gene Expression Studies in Head
    bioRxiv preprint doi: https://doi.org/10.1101/108381; this version posted February 14, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 A minimal set of internal control genes for gene expression studies in head 2 and neck squamous cell carcinoma. 1 1 1 2 3 Vinayak Palve , Manisha Pareek , Neeraja M Krishnan , Gangotri Siddappa , 2 2 1,3* 4 Amritha Suresh , Moni Abraham Kuriakose and Binay Panda 5 1 6 Ganit Labs, Bio-IT Centre, Institute of Bioinformatics and Applied Biotechnology, 7 Bangalore 560100 2 8 Mazumdar Shaw Cancer Centre and Mazumdar Shaw Centre for Translational 9 Research, Bangalore 560096 3 10 Strand Life Sciences, Bangalore 560024 11 * Corresponding author: [email protected] 12 13 Abstract: 14 Background: Selection of the right reference gene(s) is crucial in the analysis and 15 interpretation of gene expression data. In head and neck cancer, studies evaluating 16 the efficacy of internal reference genes are rare. Here, we present data for a minimal 17 set of candidates as internal control genes for gene expression studies in head and 18 neck cancer. 19 Methods: We analyzed data from multiple sources (in house whole-genome gene 20 expression microarrays, n=21; TCGA RNA-seq, n=42, and published gene 21 expression studies in head and neck tumors from literature) to come up with a set of 22 genes (discovery set) for their stable expression across tumor and normal tissues.
    [Show full text]
  • Alterations of Genetic Variants and Transcriptomic Features of Response to Tamoxifen in the Breast Cancer Cell Line
    Alterations of Genetic Variants and Transcriptomic Features of Response to Tamoxifen in the Breast Cancer Cell Line Mahnaz Nezamivand-Chegini Shiraz University Hamed Kharrati-Koopaee Shiraz University https://orcid.org/0000-0003-2345-6919 seyed taghi Heydari ( [email protected] ) Shiraz University of Medical Sciences https://orcid.org/0000-0001-7711-1137 Hasan Giahi Shiraz University Ali Dehshahri Shiraz University of Medical Sciences Mehdi Dianatpour Shiraz University of Medical Sciences Kamran Bagheri Lankarani Shiraz University of Medical Sciences Research Keywords: Tamoxifen, breast cancer, genetic variants, RNA-seq. Posted Date: August 17th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-783422/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/33 Abstract Background Breast cancer is one of the most important causes of mortality in the world, and Tamoxifen therapy is known as a medication strategy for estrogen receptor-positive breast cancer. In current study, two hypotheses of Tamoxifen consumption in breast cancer cell line (MCF7) were investigated. First, the effect of Tamoxifen on genes expression prole at transcriptome level was evaluated between the control and treated samples. Second, due to the fact that Tamoxifen is known as a mutagenic factor, there may be an association between the alterations of genetic variants and Tamoxifen treatment, which can impact on the drug response. Methods In current study, the whole-transcriptome (RNA-seq) dataset of four investigations (19 samples) were derived from European Bioinformatics Institute (EBI). At transcriptome level, the effect of Tamoxifen was investigated on gene expression prole between control and treatment samples.
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • Nuclear Factor-Erythroid-2 Related Transcription Factor-1 (Nrf1) Is Regulated MARK by O-Glcnac Transferase
    Free Radical Biology and Medicine 110 (2017) 196–205 Contents lists available at ScienceDirect Free Radical Biology and Medicine journal homepage: www.elsevier.com/locate/freeradbiomed Original article Nuclear factor-erythroid-2 related transcription factor-1 (Nrf1) is regulated MARK by O-GlcNAc transferase Jeong Woo Hana,1, Joshua L. Valdeza,1, Daniel V. Hoa, Candy S. Leea, Hyun Min Kima, ⁎ Xiaorong Wangb, Lan Huangb,Jefferson Y. Chana, a Department of Laboratory Medicine and Pathology, University of California, Irvine, D440 Medical Sciences, Irvine, CA 92697, USA b Departments of Physiology and Biophysics, University of California, Irvine, D440 Medical Sciences, Irvine, CA 92697, USA ARTICLE INFO ABSTRACT Keywords: The Nrf1 (Nuclear factor E2-related factor 1) transcription factor performs a critical role in regulating cellular Oxidative stress homeostasis. Using a proteomic approach, we identified Host Cell Factor-1 (HCF1), a co-regulator of tran- O-GlcNAcylation scription, and O-GlcNAc transferase (OGT), the enzyme that mediates protein O-GlcNAcylation, as cellular OGT partners of Nrf1a, an isoform of Nrf1. Nrf1a directly interacts with HCF1 through the HCF1 binding motif Transcription factor (HBM), while interaction with OGT is mediated through HCF1. Overexpression of HCF1 and OGT leads to Protein stability increased Nrf1a protein stability. Addition of O-GlcNAc decreases ubiquitination and degradation of Nrf1a. Transcriptional activation by Nrf1a is increased by OGT overexpression and treatment with PUGNAc. Together, these data suggest that OGT can act as a regulator of Nrf1a. 1. Introduction recognized as an essential co-factor for various transcription factors, and it is involved in regulating a plethora of cellular processes including O-GlcNAc transferase (OGT) is a highly conserved enzyme that cell-cycle progression and gene expression [18–21].
    [Show full text]
  • Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
    cancers Review Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy Mohammed I. Y. Elmallah 1,2,* and Olivier Micheau 1,* 1 INSERM, Université Bourgogne Franche-Comté, LNC UMR1231, F-21079 Dijon, France 2 Chemistry Department, Faculty of Science, Helwan University, Ain Helwan 11795 Cairo, Egypt * Correspondence: [email protected] (M.I.Y.E.); [email protected] (O.M.) Received: 23 May 2019; Accepted: 18 June 2019; Published: 19 June 2019 Abstract: One of the main characteristics of carcinogenesis relies on genetic alterations in DNA and epigenetic changes in histone and non-histone proteins. At the chromatin level, gene expression is tightly controlled by DNA methyl transferases, histone acetyltransferases (HATs), histone deacetylases (HDACs), and acetyl-binding proteins. In particular, the expression level and function of several tumor suppressor genes, or oncogenes such as c-Myc, p53 or TRAIL, have been found to be regulated by acetylation. For example, HATs are a group of enzymes, which are responsible for the acetylation of histone proteins, resulting in chromatin relaxation and transcriptional activation, whereas HDACs by deacetylating histones lead to chromatin compaction and the subsequent transcriptional repression of tumor suppressor genes. Direct acetylation of suppressor genes or oncogenes can affect their stability or function. Histone deacetylase inhibitors (HDACi) have thus been developed as a promising therapeutic target in oncology. While these inhibitors display anticancer properties in preclinical models, and despite the fact that some of them have been approved by the FDA, HDACi still have limited therapeutic efficacy in clinical terms. Nonetheless, combined with a wide range of structurally and functionally diverse chemical compounds or immune therapies, HDACi have been reported to work in synergy to induce tumor regression.
    [Show full text]
  • Supplementary Table S1. Correlation Between the Mutant P53-Interacting Partners and PTTG3P, PTTG1 and PTTG2, Based on Data from Starbase V3.0 Database
    Supplementary Table S1. Correlation between the mutant p53-interacting partners and PTTG3P, PTTG1 and PTTG2, based on data from StarBase v3.0 database. PTTG3P PTTG1 PTTG2 Gene ID Coefficient-R p-value Coefficient-R p-value Coefficient-R p-value NF-YA ENSG00000001167 −0.077 8.59e-2 −0.210 2.09e-6 −0.122 6.23e-3 NF-YB ENSG00000120837 0.176 7.12e-5 0.227 2.82e-7 0.094 3.59e-2 NF-YC ENSG00000066136 0.124 5.45e-3 0.124 5.40e-3 0.051 2.51e-1 Sp1 ENSG00000185591 −0.014 7.50e-1 −0.201 5.82e-6 −0.072 1.07e-1 Ets-1 ENSG00000134954 −0.096 3.14e-2 −0.257 4.83e-9 0.034 4.46e-1 VDR ENSG00000111424 −0.091 4.10e-2 −0.216 1.03e-6 0.014 7.48e-1 SREBP-2 ENSG00000198911 −0.064 1.53e-1 −0.147 9.27e-4 −0.073 1.01e-1 TopBP1 ENSG00000163781 0.067 1.36e-1 0.051 2.57e-1 −0.020 6.57e-1 Pin1 ENSG00000127445 0.250 1.40e-8 0.571 9.56e-45 0.187 2.52e-5 MRE11 ENSG00000020922 0.063 1.56e-1 −0.007 8.81e-1 −0.024 5.93e-1 PML ENSG00000140464 0.072 1.05e-1 0.217 9.36e-7 0.166 1.85e-4 p63 ENSG00000073282 −0.120 7.04e-3 −0.283 1.08e-10 −0.198 7.71e-6 p73 ENSG00000078900 0.104 2.03e-2 0.258 4.67e-9 0.097 3.02e-2 Supplementary Table S2.
    [Show full text]
  • Produktinformation
    Produktinformation Diagnostik & molekulare Diagnostik Laborgeräte & Service Zellkultur & Verbrauchsmaterial Forschungsprodukte & Biochemikalien Weitere Information auf den folgenden Seiten! See the following pages for more information! Lieferung & Zahlungsart Lieferung: frei Haus Bestellung auf Rechnung SZABO-SCANDIC Lieferung: € 10,- HandelsgmbH & Co KG Erstbestellung Vorauskassa Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 Zuschläge F. +43(0)1 489 3961-7 [email protected] • Mindermengenzuschlag www.szabo-scandic.com • Trockeneiszuschlag • Gefahrgutzuschlag linkedin.com/company/szaboscandic • Expressversand facebook.com/szaboscandic PSMD10 Antibody, Biotin conjugated Product Code CSB-PA018899LD01HU Abbreviation 26S proteasome non-ATPase regulatory subunit 10 Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. Uniprot No. O75832 Immunogen Recombinant Human 26S proteasome non-ATPase regulatory subunit 10 protein (1-226AA) Raised In Rabbit Species Reactivity Human Tested Applications ELISA Relevance Acts as a chaperone during the assembly of the 26S proteasome, specifically of the PA700/19S regulatory complex (RC). In the initial step of the base subcomplex assembly is part of an intermediate PSMD10:PSMC4:PSMC5:PAAF1 module which probably assembles with a PSMD5:PSMC2:PSMC1:PSMD2 module. Independently of the proteasome, regulates EGF-induced AKT activation through inhibition of the RHOA/ROCK/PTEN pahway, leading to prolonged AKT activation. Plays an important role in RAS-induced tumorigenesis. Acts as an proto-oncoprotein by being involved in negative regulation of tumor suppressors RB1 and p53/TP53. Overexpression is leading to phosphorylation of RB1 and proteasomal degradation of RB1. Regulates CDK4-mediated phosphorylation of RB1 by competing with CDKN2A for binding with CDK4. Facilitates binding of MDM2 to p53/TP53 and the mono- and polyubiquitination of p53/TP53 by MDM2 suggesting a function in targeting the TP53:MDM2 complex to the 26S proteasome.
    [Show full text]
  • Cancer Vulnerabilities Unveiled by Genomic Loss
    Cancer Vulnerabilities Unveiled by Genomic Loss The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Nijhawan, Deepak, Travis I. Zack, Yin Ren, Matthew R. Strickland, Rebecca Lamothe, Steven E. Schumacher, Aviad Tsherniak, et al. “Cancer Vulnerabilities Unveiled by Genomic Loss.” Cell 150, no. 4 (August 2012): 842–854. © 2012 Elsevier Inc. As Published http://dx.doi.org/10.1016/j.cell.2012.07.023 Publisher Elsevier B.V. Version Final published version Citable link http://hdl.handle.net/1721.1/91899 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Cancer Vulnerabilities Unveiled by Genomic Loss Deepak Nijhawan,1,2,7,9,10 Travis I. Zack,1,2,3,9 Yin Ren,5 Matthew R. Strickland,1 Rebecca Lamothe,1 Steven E. Schumacher,1,2 Aviad Tsherniak,2 Henrike C. Besche,4 Joseph Rosenbluh,1,2,7 Shyemaa Shehata,1 Glenn S. Cowley,2 Barbara A. Weir,2 Alfred L. Goldberg,4 Jill P. Mesirov,2 David E. Root,2 Sangeeta N. Bhatia,2,5,6,7,8 Rameen Beroukhim,1,2,7,* and William C. Hahn1,2,7,* 1Departments of Cancer Biology and Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA 2Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA 3Biophysics Program, Harvard University, Boston, MA 02115, USA 4Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA 5Harvard-MIT Division of Health Sciences and Technology 6David H.
    [Show full text]
  • Human Cumulus Cells in Long-Term in Vitro Culture Reflect Differential
    cells Article Human Cumulus Cells in Long-Term In Vitro Culture Reflect Differential Expression Profile of Genes Responsible for Planned Cell Death and Aging—A Study of New Molecular Markers Bła˙zejChermuła 1, Wiesława Kranc 2 , Karol Jopek 3, Joanna Budna-Tukan 3 , Greg Hutchings 2,4, Claudia Dompe 3,4, Lisa Moncrieff 3,4 , Krzysztof Janowicz 2,4, Małgorzata Józkowiak 5, Michal Jeseta 6 , Jim Petitte 7 , Paul Mozdziak 8 , Leszek Pawelczyk 1, Robert Z. Spaczy ´nski 1 and Bartosz Kempisty 2,3,6,9,* 1 Division of Infertility and Reproductive Endocrinology, Department of Gynecology, Obstetrics and Gynecological Oncology, Poznan University of Medical Sciences, 33 Polna St., 60-535 Poznan, Poland; [email protected] (B.C.); [email protected] (L.P.); [email protected] (R.Z.S.) 2 Department of Anatomy, Poznan University of Medical Sciences, 6 Swiecickiego St., 60-781 Poznan, Poland; [email protected] (W.K.); [email protected] (G.H.); [email protected] (K.J.) 3 Department of Histology and Embryology, Poznan University of Medical Sciences, 6 Swiecickiego St., 60-781 Poznan, Poland; [email protected] (K.J.); [email protected] (J.B.-T.); [email protected] (C.D.); l.moncrieff[email protected] (L.M.) 4 The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK 5 Department of Toxicology, Poznan University of Medical Sciences, 30 Dojazd St., 60-631 Poznan, Poland; [email protected] 6 Department of Obstetrics and Gynecology, University Hospital and
    [Show full text]
  • Hypermethylation of XIAP-Associated Factor 1, a Putative Tumor Suppressor Gene from the 17P13.2 Locus, in Human Gastric Adenocarcinomas1
    [CANCER RESEARCH 63, 7068–7075, November 1, 2003] Advances in Brief Hypermethylation of XIAP-associated Factor 1, a Putative Tumor Suppressor Gene from the 17p13.2 Locus, in Human Gastric Adenocarcinomas1 Do-Sun Byun, Kyucheol Cho, Byung-Kyu Ryu, Min-Goo Lee, Min-Ju Kang, Hak-Ryul Kim, and Sung-Gil Chi2 Department of Pathology, School of Medicine, Kyung Hee University, Seoul 130-701 [D-S. B., K. C., B-K. R., M-G. L., M-J. K., S-G. C.], and Graduate School of Life Science and Biotechnology, Korea University, Seoul 136-701 [D-S. B., H-R. K.], Korea Abstract gested to play a key role in the aberrantly increased cell viability and resistance to the anticancer therapy in human cancers, whereas over- X-linked inhibitor of apoptosis (XIAP) is the most potent member of the expression seems to suppress apoptosis against a large variety of IAP family that exerts antiapoptotic effects by interfering with the activ- ities of caspases. Recently, XIAP-associated factor 1 (XAF1) and two triggers (4, 5). The human IAP family includes cIAP-1, cIAP-2, mitochondrial proteins, Smac/DIABLO and HtrA2, have been identified XIAP, NAIP, survivin, apollon, ILP2, and livin, and several members to negatively regulate the caspase-inhibiting activity of XIAP. To explore of the human IAP family including XIAP, c-IAP-1, and c-IAP-2 have the candidacy of XAF1, Smac/DIABLO, and HtrA2 as a tumor suppressor been shown to be potent inhibitors of caspase-3, -7, and -9 (2, 6, 7). in gastric tumorigenesis, we investigated the expression and mutation Of the eight known human IAP proteins, XIAP is the most potent status of the genes in 123 gastric tissues and 15 cancer cell lines.
    [Show full text]
  • PSMD10 Antibody (Center) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AW5126
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PSMD10 Antibody (Center) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AW5126 Specification PSMD10 Antibody (Center) - Product Information Application IF, WB, IHC-P,E Primary Accession O75832 Other Accession Q9Z2X2 Reactivity Human Predicted Mouse Host Rabbit Clonality Polyclonal Calculated MW H=24,16;M=25;Ra t=25 KDa Isotype Rabbit Ig Antigen Source HUMAN PSMD10 Antibody (Center) - Additional Information Gene ID 5716 Fluorescent image of Hela cells stained with PSMD10 Antibody (Center)(Cat#AW5126). Antigen Region AW5126 was diluted at 1:25 dilution. An 43-76 Alexa Fluor 488-conjugated goat anti-rabbit lgG at 1:400 dilution was used as the Other Names secondary antibody (green). Cytoplasmic 26S proteasome non-ATPase regulatory subunit 10, 26S proteasome regulatory actin was counterstained with Alexa Fluor® subunit p28, Gankyrin, p28(GANK), PSMD10 555 conjugated with Phalloidin (red). Dilution IF~~1:25 WB~~ 1:1000 IHC-P~~1:25 Target/Specificity This PSMD10 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 43-76 amino acids from the Central region of human PSMD10. Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. Western blot analysis of lysates from MCF-7, PC-3, K562 cell line (from left to right), using Storage PSMD10 Antibody (Center)(Cat. #AW5126). Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Maintain refrigerated at 2-8°C for up to 2 AW5126 was diluted at 1:1000 at each lane.
    [Show full text]
  • Identification of Genes Involved in Radioresistance of Nasopharyngeal Carcinoma by Integrating Gene Ontology and Protein-Protein Interaction Networks
    INTERNATIONAL JOURNAL OF ONCOLOGY 40: 85-92, 2012 Identification of genes involved in radioresistance of nasopharyngeal carcinoma by integrating gene ontology and protein-protein interaction networks YA GUO1, XIAO-DONG ZHU1, SONG QU1, LING LI1, FANG SU1, YE LI1, SHI-TING HUANG1 and DAN-RONG LI2 1Department of Radiation Oncology, Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Autonomous Region; 2Guang xi Medical Scientific Research Center, Guangxi Medical University, Nanning 530021, P.R. China Received June 15, 2011; Accepted July 29, 2011 DOI: 10.3892/ijo.2011.1172 Abstract. Radioresistance remains one of the important factors become potential biomarkers for predicting NPC response to in relapse and metastasis of nasopharyngeal carcinoma. Thus, it radiotherapy. is imperative to identify genes involved in radioresistance and explore the underlying biological processes in the development Introduction of radioresistance. In this study, we used cDNA microarrays to select differential genes between radioresistant CNE-2R Nasopharyngeal carcinoma (NPC) is a major malignant tumor and parental CNE-2 cell lines. One hundred and eighty-three of the head and neck region and is endemic to Southeast significantly differentially expressed genes (p<0.05) were Asia, especially Guangdong and Guangxi Provinces, and the identified, of which 138 genes were upregulated and 45 genes Mediterranean basin (1,3). Radiotherapy is the major treatment were downregulated in CNE-2R. We further employed publicly modality for nasopharyngeal carcinoma (NPC). However, in available bioinformatics related software, such as GOEAST some cases, it is radioresistant. Although microarray methods and STRING to examine the relationship among differen- have been used to assess genes involved in radioresistance in a tially expressed genes.
    [Show full text]